PACB
ANALYST COVERAGE18 analysts
HOLD
-13.0%downside to target
Buy
950%
Hold
844%
Sell
16%
9 Buy (50%)8 Hold (44%)1 Sell (6%)
Full report →
Key MetricsTTM
Market Cap$357.19M
Revenue TTM$160.03M
Net Income TTM-$128.58M
Free Cash Flow-$116.21M
Gross Margin37.1%
Operating Margin-101.7%
Net Margin-80.3%
Return on Equity-488.4%
Return on Assets-16.4%
Debt / Equity297.29
Current Ratio5.65
EPS TTM$-0.42
PRICE
Prev Close
1.15
Open
1.16
Day Range1.12 – 1.19
1.12
1.19
52W Range0.85 – 2.73
0.85
2.73
16% of range
VOLUME & SIZE
Avg Volume
6.1M
FUNDAMENTALS
P/E Ratio
-2.8x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
2.74
High vol
TECHNICAL
RSI (14)
33
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 21
DEx-Dividend
In 90 days
Aug 18
PDividend Pay
In 168 days
Nov 4

PACB News

About

Pacific Biosciences of California, Inc. is empowering life scientists with highly accurate long-read sequencing. The company's innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio® sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology.

Industry
Analytical Laboratory Instrument Manufacturing
Stephen TurnerCo-Founder
Christian O. HenryPresident, Chief Executive Officer & Director
David RuggieroGlobal Head of Sales & Service
James R. GibsonCFO & Principal Accounting Officer
Mark Van OeneChief Operating Officer
Brett AtkinsGeneral Counsel & Corporate Secretary
Natalie WelchChief People Officer